Jump to content

Nadav Ahituv

Add links
From Wikipedia, the free encyclopedia

Nadav Ahituv is the Director for the Institute for Human Genetics at the University of California, San Francisco (USCF).[1][2][3] He is also a Professor in the Department of Bioengineering and Therapeutic Sciences and leads the Ahituv Lab at University of California, San Francisco (USCF).[1][4]

Early life and education

[edit]

Ahituv received his PhD with distinction in human genetics from Tel-Aviv University, where he worked on hereditary hearing loss.[1][3][2]

Research

[edit]

Ahituv developed cis-regulation therapy (CRT) for genetic diseases that are caused due to changes in gene dosage [5][6] and adipose manipulation transplantation (AMT) that engineers fat cells and implants them for therapeutic benefits.[7]

The Ahituv Lab investigates gene regulatory elements and their relationship to human diversity and disease.[4] His lab also focuses on identifying gene regulatory elements and linking nucleotide variation within them to various phenotypes, including morphological differences between species, drug response, and human disease.[8] The lab is one of the developers of massively parallel reporter assays (MPRAs) that allow for high-throughput functional characterization of gene regulatory elements.[9]

Awards and honors

[edit]

In 2014, Ahituv received the ASCPT Leon I. Goldberg young investigator award from The American Society for Clinical Pharmacology and Therapeutics.[10][1] In 2024, Ahituv received the Scientific Achievement Award from the The American Society of Human Genetics (ASHG).[11]

References

[edit]
  1. ^ a b c d "Nadav Ahituv | UCSF Profiles". profiles.ucsf.edu. Retrieved 2024-03-05.
  2. ^ a b "Nadav Ahituv". Simons Institute for the Theory of Computing. Retrieved 2024-03-05.
  3. ^ a b "Speaker Template". PMWC Precision Medicine World Conference. Retrieved 2024-03-05.
  4. ^ a b "About · Ahituv Lab". Ahituv Lab. Retrieved 2024-03-05.
  5. ^ Matharu, Navneet (2018-12-13). "CRISPR-mediated activation of a promoter or enhancer rescues obesity caused by haploinsufficiency". Science. 363 (6424): eaau0629. doi:10.1126/science.aau0629. ISSN 1095-9203. PMID 30545847. S2CID 256746336.
  6. ^ Matharu, Navneet; Ahituv, Nadav (2020-11-01). "Modulating gene regulation to treat genetic disorders". Nature Reviews Drug Discovery. 19 (11): 757–775. doi:10.1038/s41573-020-0083-7. ISSN 1474-1784. PMID 33020616. S2CID 256746336.
  7. ^ Nguyen, Hai (2023-03-29). "Implantation of engineered adipocytes that outcompete tumors for resources suppresses cancer progression". bioRxiv. doi:10.1101/2023.03.28.534564. PMID 37034710.
  8. ^ "Nadav Ahituv, PhD". UCSF Institute for Human Genetics. Retrieved 2024-03-05.
  9. ^ Inoue, Fumitaka; Ahituv, Nadav (2015-09-01). "Decoding enhancers using massively parallel reporter assays". Genomics. 106 (3): 159–164. doi:10.1016/j.ygeno.2015.06.005. PMC 4540663. PMID 26072433.
  10. ^ "Nadav Ahituv, PhD | Department of Medicine". medicine.ucsf.edu. Retrieved 2024-03-05.
  11. ^ "2024 ASHG Awards". American Society of Human Genetics. Retrieved 7 October 2024.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Nadav_Ahituv&oldid=1254102589"